Patents Examined by Jared D Barsky
  • Patent number: 10098961
    Abstract: An injectable hyaluronic acid composition including a hyaluronic acid; a local anesthetic selected from the group of amide and ester type local anesthetics or a combination thereof; and an ascorbic acid derivative in an amount which prevents or reduces the effect on the viscosity and/or elastic modulus G? of the composition caused by the local anesthetic upon sterilization by heat. Further, the medical and non-medical, such as cosmetic, use of such a composition, and a method of manufacturing such a composition.
    Type: Grant
    Filed: February 3, 2012
    Date of Patent: October 16, 2018
    Assignee: Q-MED AB
    Inventors: Åsa Wiebensjö, Katarina Edsman
  • Patent number: 10085977
    Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: October 2, 2018
    Assignees: The Board of Trustees of the Univerity of Illinois, Vanquish Oncology, Inc.
    Inventors: Paul J. Hergenrother, Rachel C. Botham, Timothy M. Fan, Mark J. Gilbert, Michael K. Handley, Howard S. Roth, Theodore M. Tarasow
  • Patent number: 10080735
    Abstract: The present invention relates to purified 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt thereof, and a method for preparing such compound. The compound has at least 90% (w/w) purity. The present invention is also directed to a pharmaceutical composition comprises the purified compound and a pharmaceutically acceptable carrier. The present invention is further directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: September 25, 2018
    Assignee: Olatec Therapeutics LLC
    Inventor: Joseph St. Laurent
  • Patent number: 10071162
    Abstract: The present invention is directed to a preserved liquid aqueous pharmaceutical composition comprising one or more etherified cyclodextrin derivatives; one or more water-soluble preservatives; preferably selected from the group consisting of sorbic acid or salts thereof, preferably sodium sorbate, potassium sorbate, calcium sorbate; benzoic acid or salts thereof, preferably sodium benzoate; benzalkonium chloride; benzethonium chloride; cetylpyridinium chloride; sodium metabisulfite; sodium acetate; parabenes and salts thereof, preferably methylparabene, ethylparabene, propylparabene, butylparabene, butylparabene sodium; or combinations thereof; and at least one pharmaceutically active compound which is poorly water-soluble, very poorly water-soluble or water-insoluble.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: September 11, 2018
    Inventors: Michael Aven, Tim Lukas
  • Patent number: 10021879
    Abstract: Fumigant compositions including hexafluoropropylene oxide (HFPO) and methods of preparing such compositions are provided. The fumigant compositions may be suitable for use as soil fumigant compositions and structural fumigant compositions against a variety of undesirable species such as weeds, nematodes, pathogens, animals and insects. The fumigant compositions also have low toxicity and low Global Warming Potential (GWP).
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: July 17, 2018
    Assignee: Honeywell International Inc.
    Inventors: David Nalewajek, Andrew J. Poss, Cheryl L. Cantlon
  • Patent number: 10005754
    Abstract: A new crystalline form of spirodiclofen of formula (I), the crystal preparation process, the analyzes of the crystal through various analytical methods and using the crystal to prepare stable agrochemical formulation. The invention also describes the use of various solvents towards the crystalline form preparation conditions.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: June 26, 2018
    Inventor: James Timothy Bristow
  • Patent number: 9980975
    Abstract: The present invention describes novel and improved dosage forms containing fluticasone propionate for the treatment of conditions associated with inflammation of the esophagus.
    Type: Grant
    Filed: January 22, 2015
    Date of Patent: May 29, 2018
    Assignee: EMS S.A.
    Inventors: Giancarlo Santus, Leticia Khater Covesi, Luca Donadoni, Christina Ecclissato, Roberto Amazonas
  • Patent number: 9982008
    Abstract: The present invention relates to obeticholic acid: or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a FXR mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing HDL cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis. The present invention also relates to processes for the synthesis of obeticholic acid.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: May 29, 2018
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: André Steiner, Heidi Waenerlund Poulsen, Emilie Jolibois, Melissa Rewolinski, Ralf Gross, Emma Sharp, Fiona Dubas-Fisher, Alex Eberlin
  • Patent number: 9968568
    Abstract: This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: May 15, 2018
    Inventor: Herriot Tabuteau
  • Patent number: 9962357
    Abstract: The present disclosure describes novel PKC-? activators chosen from halogenated esters of unsaturated fatty acids derivatives thereof, including halogenated esters of both polyunsaturated and monunsaturated fatty acids and derivatives thereof. The disclosure further relates to compositions, kits, and methods for treatment using the halogenated esters.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: May 8, 2018
    Assignee: West Virginia University
    Inventors: Thomas J. Nelson, Daniel L. Alkon
  • Patent number: 9951089
    Abstract: The present invention provides fatty acid amide hydrolase inhibitors, solid forms thereof, compositions thereof, and methods of making and using the same.
    Type: Grant
    Filed: February 25, 2015
    Date of Patent: April 24, 2018
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Brian C. Austad, Louis Grenier, Michael J. Grogan, Tao Liu, Priscilla L. White, Theodore A. Martinot, Lin-Chen Yu
  • Patent number: 9950987
    Abstract: The present invention provides novel aspirin derivatives useful for preventing and/or treating cancer. The novel compounds of this invention may be particularly useful for the prevention and/or treatment of cancers affecting the gastrointestinal system, such as colorectal cancer.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: April 24, 2018
    Assignee: North Carolina Agricultural and Technical State University
    Inventor: Shengmin Sang
  • Patent number: 9943477
    Abstract: The present invention is directed to an emulsion composition, comprising: (i) from about 0.01 to about 1% by weight of at least one aromatic alcohol; (ii) from about 0.01 to about 1% by weight of at least one aromatic carboxylic acid; and (iii) from about 0.01 to about 0.5 % by weight of at least one chlorophenyl glyceryl ether; and wherein the composition does not require use of parabens, ethanol and/or glycols in order to preserve the composition.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: April 17, 2018
    Assignee: L'Oreal
    Inventors: Catherine Chiou, Joyce Beauchamp
  • Patent number: 9931350
    Abstract: Cationic steroidal antimicrobials (“CSAs” or “ceragenins”) and methods of making and using the same. Particularly advantageous uses include treating infections in patient and sub-patient populations, especially those having a bone disease, a broken bone, a bone infection, or a bone implant.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: April 3, 2018
    Inventors: Paul B. Savage, Carl Genberg
  • Patent number: 9926322
    Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: March 27, 2018
    Inventors: Shingo Yamamoto, Toshio Yoshizawa
  • Patent number: 9925282
    Abstract: Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula: wherein X is OH, C1-C6 alkoxyl; Y and Z are independently selected from a C1-C6 alkyl, C1-C6 alkoxyl, halogen, un-substituted or C1-C6 substituted amine, 18F, 19F, or H; and n is 1, 2, or 3; and wherein for structure (I), if n are both 1 and Y and Z are both H and X is OH.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: March 27, 2018
    Assignee: The General Hospital Corporation
    Inventors: David R. Elmaleh, Timothy Shoup
  • Patent number: 9913825
    Abstract: A method of ameliorating symptoms of uremia includes administering a therapeutic agent including beraprost or each isomer constituting beraprost, or a salt thereof as an effective ingredient to an animal belonging to the Family Canidae, wherein an effective dosage is a dosage that does not significantly lower blood pressure.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: March 13, 2018
    Assignee: Toray Industries, Inc.
    Inventors: Masahiko Takenaka, Yoshihisa Yamane, Nobutaka Ida, Hajimu Kurumatani
  • Patent number: 9913832
    Abstract: A novel function for the p53 gene related to resolution of deep venous thrombosis is disclosed herein. Lack of the p53 gene results in impaired thrombus resolution in a clinically relevant in vivo model of deep venous thrombus resolution. It is further shown that augmentation of p53 activity with quinacrine accelerates thrombus resolution in vivo, and that this beneficial effect is completely dependent on p53. p53-based therapy is therefore provided to accelerate thrombus resolution in patients, and to prevent or ameliorate the debilitating long-term complications of deep venous thrombosis such as post-thrombotic syndrome.
    Type: Grant
    Filed: October 1, 2010
    Date of Patent: March 13, 2018
    Inventor: Rajabrata Sarkar
  • Patent number: 9907807
    Abstract: Topical pharmaceutical compositions are described comprising, based on the total weight of the composition: a) 0.01 to 0.2 wt. % of mometasone furoate, b) 5 to 18 wt. % of hexylene glycol, c) 20 to 40 wt. % of water, and d) 25 to 70 wt. % of an oil phase. Said compositions are stable and can be safely and easily applied over large surface areas of the skin in an acceptable way by the general patient population for the treatment or prevention of psoriasis, atopic dermatitis (atopic eczema) and other skin disorders or diseases.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: March 6, 2018
    Assignee: ALMIRALL, S.A.
    Inventors: Fritjof Evers, Henning Mallwitz, Ricarda Wessel, Christoph Willers
  • Patent number: 9890189
    Abstract: The present invention provides compounds according to formula I: and pharmaceutically acceptable salts thereof. For compounds of formula I, R1 and R2 are independently selected from the group consisting of H, —C(?O)—(CH2)2-aryl, and —C(?O)—(CH2)n—C(?O)—NH-aryl. The subscript n is from 2 to 6. R3 is selected from the group consisting of H and —C(?O)—O—R4; and R4 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, arylalkyl, substituted arylalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl and substituted heteroalkyl. Compounds are provided wherein at least one of R1 and R2 is other than H. Pharmaceutical compositions, methods for inhibiting the growth of cancer cells, and methods for the treatment of cancer are also provided.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: February 13, 2018
    Assignee: BoYen Therapeutics, Inc.
    Inventor: Laurence I. Wu